TILT Holdings Reports Record Second Quarter 2021 Financial Results

Rhea-AI Summary

TILT Holdings reported a record Q2 revenue of $48.5 million, a 33% year-over-year increase, alongside an adjusted EBITDA of $6.5 million, up 2.7x from Q2 2020. The growth was driven by both cannabis and inhalation accessory sales, with cannabis revenue rising 31% to $10 million and accessory revenue increasing 34% to $38.5 million. TILT reiterated its 2021 guidance of revenue between $205-$210 million and adjusted EBITDA between $30-$32 million. The company also announced a partnership with the Shinnecock Indian Nation to enter New York's cannabis market, enhancing growth opportunities.

Positive

• Record Q2 revenue of $48.5 million, a 33% YoY increase.
• Adjusted EBITDA increased to $6.5 million, a 2.7x rise from Q2 2020.
• Cannabis revenue grew 31% to $10 million.
• Inhalation and accessory revenue increased 34% to $38.5 million.
• Reiterated 2021 revenue guidance of $205-$210 million.

Negative

• Gross profit margins decreased to 27% due to increased supply chain expenses.

Record Q2 Revenue up 33% YoY to $48.5 Million

Record Q2 Adjusted EBITDA up 2.7x to $6.5 Million

Reiterates 2021 Guidance of Revenue Between $205 - $210 Million and Adjusted EBITDA Between $30 -$32 Million

PHOENIX, Aug. 24, 2021 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT" or the “Company”) (NEO:TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, is reporting its financial and operating results for the three-months and six-months ended June 30, 2021. All financial information is provided in U.S. dollars unless otherwise indicated.

“We generated another quarter of record results by continuing to execute our B2B strategy and driving synergies across our business segments,” said Gary Santo, CEO of TILT. “Our ability to cross-sell and deepen relationships with our 700+ customer base is materializing in the numbers. In fact, at the end of last year, 20% of our revenue was generated by our customers leveraging services across our cannabis inhalation and accessory businesses. By the end of Q2, that number increased to over 30%, which tells us that our strategy is working."

“Earlier today we announced a historic partnership with the Shinnecock Indian Nation to develop vertical cannabis operations in New York, marking our entrance into what is projected to be one of the largest cannabis markets in the country. I am incredibly excited for both our teams as well as the economic opportunity this will create for the Nation—this is truly what an equitable partnership should look like.”

“We remain committed to delivering shareholder value through growth and profitability. We are on track to deliver strong organic results in 2021, and given our recently awarded provisional licenses in Massachusetts, our expanded canopy, new and expanded brand partnerships, and our entry into New York, 2022 is positioned to be an even stronger year for TILT.”

Q2 2021 Financial Summary (vs. Q2 2020, where applicable)

• Revenue increased 33% to $48.5 million driven by growth in both cannabis and inhalation and accessory revenue. Cannabis revenue increased 31% to $10.0 million and inhalation and accessory revenue increased 34% to $38.5 million.
• Gross profit before fair value adjustments increased 25% to $13.1 million or 27% of revenue, compared to $10.5 million or 28.9% of revenue. Gross margins were impacted by supply chain expenses related to freight costs for the Company’s inhalation and accessory business.
• Adjusted EBITDA was up 2.7x to $6.5 million compared to $2.4 million. As a percentage of revenue, Adjusted EBITDA increased 680 basis points to 13.5% compared to 6.7%.
• At June 30, 2021, cash and cash equivalents increased 29% to $9.6 million compared to $7.4 million at December 31, 2020.

Q2 2021 Operational Highlights

• TILT’s inhalation and accessory business generated record monthly sales in April.
• Generated record quarterly flower sales in Pennsylvania.
• Launched exclusive partnership with Old Pal to bring select products to Massachusetts.
• Expanded exclusive partnership with Airo Brands to bring select products to Pennsylvania.
• Secured local approval by the City Council of Brockton for adult use cannabis sales at the Company’s Brockton dispensary.
• Appointed Gary Santo to CEO; Mark Scatterday continues serving as Chairman of the Board.

Operational Highlights Subsequent to Quarter End

• Announced partnership with the Shinnecock Indian Nation to enter New York’s cannabis market.
• Received four new provisional adult-use licenses in Massachusetts and final medical dispensary license for the Company’s Brockton location.
• Expanded partnership with Old Pal to bring select products to market in Pennsylvania.
• Announced partnership with 1906 to launch various products in three key markets: Massachusetts, Pennsylvania and Ohio.
• Commenced trading of TILT’s common shares on the more senior NEO Exchange in Canada.
• Entered into a new $10 million revolving credit facility that bears interest at Prime plus 3.5%.
• Deepened talent pool with several key new hires, including a new Chief Operating Officer, Head of Cannabis Operations and Head of Cultivation.

Earnings Call and Webcast

The Company will host a conference call today at 5:00 p.m. Eastern time to discuss its financial and operational results.

The live webcast may be accessed from the Events and Presentations menu in the Investor Relations section of the Company’s website as well as through this link. To access the conference call via telephone, please dial 1-877-705-6003. Please register at least 10 minutes prior to the scheduled start to download and install any necessary audio software.

A replay of the webcast will be available in the Past Events section of the Company’s Investor Relations website approximately 2 hours after the live event and will be archived for 30 days.

About TILT

TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 36 states in the U.S., as well as Canada, Israel, Mexico, South America and the European Union. TILT’s core businesses include Jupiter Research LLC, a wholly owned subsidiary and leader in the vaporization segment focused on hardware design, research, development and manufacturing; and cannabis operations, Commonwealth Alternative Care, Inc. in Massachusetts, Standard Farms LLC in Pennsylvania and Standard Farms Ohio, LLC in Ohio, and its partnership with the Shinnecock Indian Nation in New York. TILT is headquartered in Phoenix, Arizona. For more information, visit www.tiltholdings.com.

Forward-Looking Information

This news release contains forward-looking information based on current expectations. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information may include, without limitation, expectations regarding 2021 revenue and Adjusted EBITDA guidance, expected success of New York cannabis market, projected expansion into the Commonwealth,expectations with respect to expanding operations and solutions, the opinions or beliefs of management, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of TILT, and includes statements about, among other things, future developments, the future operations, strengths and strategy of TILT. Generally, forward looking information can be identified by the use of forward looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including TILT’s experience and perceptions of historical trends, the ability of TILT to maximize shareholder value, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances.

Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. TILT assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of TILT, and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements.

For additional information regarding forward-looking statements and their related risks, please refer to the “Risk Factors and Uncertainties” section in the Annual Information Form of the Company for the year ended on December 31, 2020, which is available on the Company’s SEDAR profile at www.sedar.com. 

Non-IFRS Financial and Performance Measures

In addition to providing financial measurements based on International Financial Reporting Standards (“IFRS”), the Company provides additional financial metrics that are not prepared in accordance with IFRS. Management uses non-IFRS financial measures, in addition to IFRS financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company’s financial performance. These non-IFRS financial measures are EBITDA and Adjusted EBITDA. Management believes that these non-IFRS financial measures reflect the Company’s ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. Management also believes that these non-IFRS financial measures enable investors to evaluate the Company’s operating results and future prospects in the same manner as management. These non-IFRS financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results. 

As there are no standardized methods of calculating these non-IFRS measures, the Company’s methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others.

Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

EBITDA and Adjusted EBITDA

EBITDA and Adjusted EBITDA are financial measures that are not defined under IFRS. The Company uses these non-IFRS financial measures, and believes they enhance an investor’s understanding of the Company’s financial and operating performance from period to period, because they exclude certain material non-cash items and certain other adjustments management believes are not reflective of the Company’s ongoing operations and performance. The Company calculates EBITDA as net income (loss), plus (minus) income taxes (recovery), plus (minus) finance expense (income), plus depreciation and amortization expense. Adjusted EBITDA excludes certain one-time, non-cash or non-operating expenses, as determined by management, including stock compensation expense, business acquisition expense, debt issuance costs, severance, unrealized (gain) loss on changes in fair value of biological assets and fair value changes in biological assets included in inventory sold.

Reconciliations of Non-IFRS Financial and Performance Measures
Adjusted EBITDA is reconciled to Net Loss below as well as the section labelled “Reconciliation of Net Income (Loss) to Non-IFRS Measures” in the Management Discussion and Analysis of the Company for the three and six months ended on June 30, 2021, which is available on the Company’s SEDAR profile at www.sedar.com. 

Selected Financial Results

Table 1: Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss)
(in US$ thousands, unaudited)
		Three Months Ended												Six Months Ended
($ thousands)		Jun 30, 2021				Mar 31, 2021				Jun 30, 2020				Jun 30, 2021				Jun 30, 2020
Revenue		$	48,506			$	46,780			$	36,436			$	95,286			$	77,061
Cost of Goods Sold			35,389				33,327				25,907				68,716				53,907
Gross Profit, Before FV Adj.			13,117				13,453				10,529				26,570				23,154
Gross Margin %, Before FV Adj.			27	%			29	%			29	%			28	%			30	%
Gain on FV of Bio. Assets			11,807				14,720				3,200				26,527				19,171
FV of Bio. Assets in Inventory Sold			(10,219	)			(13,400	)			(7,008	)			(23,619	)			(13,081	)
Gross Profit, After FV Adj.			14,705				14,773				6,721				29,478				29,244
Gross Margin %, After FV Adj.			30	%			32	%			18	%			31	%			38	%
Total Operating Expenses			15,045				13,108				15,182				28,153				29,397
Income (Loss) from Continuing Operations			(340	)			1,665				(8,461	)			1,325				(153	)
Total Other Income (Expense)			(2,622	)			(2,768	)			(2,024	)			(5,389	)			(4,236	)
Income Tax (Expense) Recovery			(1,019	)			(477	)			1,677				(1,496	)			(631	)
Net Income (Loss) from Continuing Operations		$	(3,981	)		$	(1,579	)		$	(8,808	)		$	(5,560	)		$	(5,020	)
Net (Loss) from discontinued operations, net of tax			-				-				(236	)			-				(3,973	)
Net Income (Loss)		$	(3,981	)		$	(1,579	)		$	(9,044	)		$	(5,560	)		$	(8,993	)
EBITDA, Non-IFRS			5,101				6,421				(2,859	)			11,522				10,906
Adjusted EBITDA, Non-IFRS		$	6,532			$	6,195			$	2,427			$	12,727			$	7,230

Table 2: Reconciliation of Non-IFRS Measures
(in US$ thousands, unaudited)
		Three Months Ended										Six Months Ended
($ thousands)		Jun 30, 2021			Mar 31, 2021			Jun 30, 2020				Jun 30, 2021			June 30, 2020
Net (Loss) from Continuing Operations		$	(3,981	)	$	(1,579	)	$	(8,808	)		$	(5,560	)	$	(5,020	)
Add (Deduct) Impact of:
Interest (Income)			16			(603	)		(633	)			(587	)		(1,473	)
Finance Expense			2,484			2,597			2,662				5,081			5,508
Income Tax Expense (Recovery)			1,019			477			(1,677	)			1,496			631
Depreciation and Amortization			5,563			5,529			5,597				11,092			11,260
Total Adjustments			9,082			8,000			5,949				17,082			15,926
EBITDA (Non-IFRS)		$	5,101		$	6,421		$	(2,859	)		$	11,522		$	10,906
Add (Deduct) Impact of:
Share-based compensation			675			882			1,310				1,557			1,927
Severance			17			-			155				17			207
(Gain) Loss on Sale of Assets			(8	)		67			-				59			-
Lease Restructuring Costs			-			(14	)		-				(14	)		267
Deferred Rent Adjustment			-			(548	)		-				(548	)		-
Legal Settlement			2,325			2			-				2,327			-
Unrealized (Gain) Loss on Investment in Equity Security			53			705			(91	)			758			(91	)
Loss on Loan Receivable			-			-			104				-			104
One time operating expense adjustments			(43	)		-			-				(43	)		-
Unrealized (Gain) on Changes in FV of Bio. Assets			(11,807	)		(14,720	)		(3,200	)			(26,527	)		(19,171	)
FV Changes in Bio. Assets Included in Inventory Sold			10,219			13,400			7,008				23,619			13,081
Total Adjustments			1,431			(226	)		5,286				1,205			(3,676	)
Adjusted EBITDA (Non-IFRS)		$	6,532		$	6,195		$	2,427			$	12,727		$	7,230

Table 3: Condensed Interim Consolidated Statements of Cash Flows
(in US$ thousands, unaudited)
					2021				2020
Cash provided by (used in) operating activities - continuing operations				$	2,345			$	13,486
Cash (used in) operating activities - discontinuing operations					-				(3,271	)
Net cash provided by operating activities					2,345				10,215
Cash (used in) provided by investing activities - continuing operations					1,274				14
Cash (used in) investing activities - discontinuing operations					-				(96	)
Net cash (used in) provided by investing activities					1,274				(82	)
Cash (used in) financing activities - continuing operations					(1,485	)			(1,312	)
Cash (used in) financing activities - discontinuing operations					-				(145	)
Net cash (used in) financing activities					(1,485	)			(1,457	)
Effect of foreign exchange on cash and cash equivalents					11				(739	)
Net change in cash and cash equivalents					2,145				7,937
Cash and cash equivalents, beginning of year					7,427				2,580
Cash and cash equivalents, end of year				$	9,572			$	10,517

Table 4: Condensed Interim Consolidated Statements of Financial Position (Select Items)
(in US$ thousands, unaudited)
	($ thousands)		Jun 30, 2021			Dec 31, 2020
	Cash and Cash Equivalents		$	9,572		$	7,427
	Biological Assets			13,904			11,201
	Inventory			70,602			52,634
	Total Current Assets			115,741			101,889
	Property, Plant & Equipment, Net			65,804			66,795
	Total Assets			435,478			429,604
	Total Current Liabilities			53,881			44,488
	Total Long-Term Liabilities			102,390			102,069
	Total Shareholders’ Equity			279,207			283,047
	Working Capital			61,860			57,401

Investor Relations Contact:
Taylor Allison
investors@tiltholdings.com

Media Contact:
Juliet Fairbrother
MATTIO Communications
juliet@mattio.com
631.338.5343

FAQ

What were TILT Holdings' Q2 2021 revenue results?

TILT Holdings reported Q2 2021 revenue of $48.5 million, representing a 33% increase year-over-year.

What is TILT Holdings' adjusted EBITDA for Q2 2021?

The adjusted EBITDA for Q2 2021 was $6.5 million, up 2.7 times from the previous year.

What is TILT Holdings' revenue guidance for 2021?

TILT Holdings reaffirmed its revenue guidance for 2021 to be between $205 million and $210 million.

What partnership did TILT Holdings announce?

TILT announced a partnership with the Shinnecock Indian Nation to develop cannabis operations in New York.

How did TILT's cannabis revenue perform in Q2 2021?

Cannabis revenue increased by 31% to $10 million in Q2 2021.